NDC80 / HEC1 promotes macrophage polarization and predicts glioma prognosis via single‐cell RNA ‐seq and in vitro experiment
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14850 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Weijie Ye und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, RNA-Seq, Macrophages. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hunan Provincial Natural Science Foundation of China, China Postdoctoral Science Foundation, Hunan Youth Science and Technology Talent Project.
Abstract (Originalsprache)
Introduction
Glioma is the most frequent and lethal form of primary brain tumor. The molecular mechanism of oncogenesis and progression of glioma still remains unclear, rendering the therapeutic effect of conventional radiotherapy, chemotherapy, and surgical resection insufficient. In this study, we sought to explore the function of HEC1 (highly expressed in cancer 1) in glioma; a component of the NDC80 complex in glioma is crucial in the regulation of kinetochore.
Methods
Bulk RNA and scRNA‐seq analyses were used to infer HEC1 function, and in vitro experiments validated its function.
Results
HEC1 overexpression was observed in glioma and was indicative of poor prognosis and malignant clinical features, which was confirmed in human glioma tissues. High HEC1 expression was correlated with more active cell cycle, DNA‐associated activities, and the formation of immunosuppressive tumor microenvironment, including interaction with immune cells, and correlated strongly with infiltrating immune cells and enhanced expression of immune checkpoints. In vitro experiments and RNA‐seq further confirmed the role of HEC1 in promoting cell proliferation, and the expression of DNA replication and repair pathways in glioma. Coculture assay confirmed that HEC1 promotes microglial migration and the transformation of M1 phenotype macrophage to M2 phenotype.
Conclusion
Altogether, these findings demonstrate that HEC1 may be a potential prognostic marker and an immunotherapeutic target in glioma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, China.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
- Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
- College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
ORCID-Profile: Quan Cheng, Xiaoping Chen
Förderung
- Hunan Provincial Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Hunan Youth Science and Technology Talent Project
- Fundamental Research Funds for Central Universities of the Central South University
Zitieren
APA
Ye, W., Liang, X., Chen, G., Chen, Q., Zhang, H., Zhang, N., Huang, Y., Cheng, Q., & Chen, X. (2024). NDC80 / HEC1 promotes macrophage polarization and predicts glioma prognosis via single‐cell RNA ‐seq and in vitro experiment. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14850
Vancouver
Ye W, Liang X, Chen G, Chen Q, Zhang H, Zhang N, et al. NDC80 / HEC1 promotes macrophage polarization and predicts glioma prognosis via single‐cell RNA ‐seq and in vitro experiment. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14850
BibTeX
@article{Ye2024,
author = {Ye, Weijie and Liang, Xisong and Chen, Ge and Chen, Qiao and Zhang, Hao and Zhang, Nan and Huang, Yuanfei and Cheng, Quan and Chen, Xiaoping},
title = {NDC80 / HEC1 promotes macrophage polarization and predicts glioma prognosis via single‐cell RNA ‐seq and in vitro experiment},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14850}
}
EUVIMED